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Background. Recent evidence suggested that associating liver partition and portal vein ligation for staged
hepatectomywith a partial split could effectively induce the same degree of future liver remnant hypertrophy as
a complete split in non-cirrhotic and non-cholestatic livers with better postoperative safety profiles. Our aim
was to evaluate if the same phenomenon could be applied to hepatitis-related chronic liver diseases.
Methods. In the study, 25 patients who underwent associating liver partition and portal vein ligation for
staged hepatectomy from October 2013 to January 2016 for hepatocellular carcinoma were analyzed.
Partial-associating liver partition and portal vein ligation for staged hepatectomy (n = 12) was defined as
50–80% of the transection surface split and complete-associating liver partition and portal vein ligation
for staged hepatectomy (n = 13) was split down to inferior vena cava. Perioperative outcomes stratified by
split completeness were evaluated.
Results. There was no significant difference in operating times and blood loss for stage I and II operations
between complete-associating liver partition and portal vein ligation for staged hepatectomy and partial-
associating liver partition and portal vein ligation for staged hepatectomy. All patients underwent stage II
operation without any inter-stage complications. Complete split induced greater future liver remnant
hypertrophy than partial split (hypertrophy rate: 31.2 vs 17.5 mL/day, P = .022) with more pronounced
effect in chronic hepatitis (P = .007) than cirrhosis (P = .283). Complete-associating liver partition and
portal vein ligation for staged hepatectomy was more likely to attain a future liver remnant/estimated
standard liver volume ratio >35% within 10 days (76.9% vs 33.3%, P = .024) and proceed to stage II
within 14 days after stage I (100% vs 58.4%, P = .009). The overall postoperative morbidity ($grade
3a) after stage II was 16% (complete versus partial split: 7.7% vs 25%, P = .238) and hospital mor-
tality after stage II was 8% (complete versus partial split: 0% vs 16.7%, P = .125).
Conclusion. Complete-associating liver partition and portal vein ligation for staged hepatectomy induced
more rapid future liver remnant hypertrophy than partial-associating liver partition and portal vein
ligation for staged hepatectomy without increased perioperative risk in chronic liver diseases. (Surgery
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358 Chan et alASSOCIATING LIVER PARTITION and portal vein ligation
for staged hepatectomy (ALPPS) has been intro-
duced recently as a novel procedure to augment
future liver remnant (FLR) in patients with mar-
ginal liver volume contemplating for major hepa-
tectomy.1,2 Early experience of ALPPS has been
hampered by the high incidence of postoperative
complications, such as bile leakage, infection,
and the high incidence of mortality.3,4 With cumu-
lative experience and modification of operative
techniques, the short-term outcomes of ALPPS
have improved, resulting in a postoperative
morbidity rate of 28–31% and a mortality rate
ranging from 7–9%.5-7 Additional study is needed
regarding the development of this new surgical
technique relates to the completeness of paren-
chymal split and the degree of FLR hypertrophy.
Recent evidence demonstrated that partial split
(defined as 50–80% of the complete transection
surface) was associated with the same amount of
FLR hypertrophy as a complete split, and with
the benefit of lower postoperative morbidity and
mortality in non-cirrhotic and non-cholestatic
livers.8 However, there is insufficient data on the
impact of split on liver hypertrophy in chronic liver
diseases. We hereby report our experience of split
completeness and its impact on the degree of FLR
hypertrophy in patients with viral hepatitis-related
hepatocellular carcinoma.METHODS
From October 2013 to January 2016, a total of
25 patients underwent the ALPPS procedure for
hepatocellular carcinoma (HCC) at the Depart-
ment of Surgery at the University of Hong Kong.
With the approval from hospital ethics committee,
we collected data prospectively including patient
characteristics, operative details, and postoperative
outcomes. Patients were divided into 2 groups
according to the in situ split completeness for
analysis. The selection criteria for ALPPS proced-
ure in our center were Child-Pugh A liver cirrhosis
or normal liver biochemistry, indocyanine green
retention rate <20% at 15 minutes, FLR/estimated
standard liver volume (ESLV) ratio <35% for
unilobar lesion/<40% for bilobar lesions that
required tumor clearance in FLR, and platelet
count $100 3 109/L. The ESLV was calculated by
the Urata formula.9
Operative techniques for ALPPS. The operative
techniques for stage I procedure in our center
were described previously.10 In summary, we used
the anterior approach for stage I procedures to
minimize adhesion formation and to preventiatrogenic tumor rupture during right liver mobili-
zation for large sized tumors. In situ split was per-
formed using a Cavitron Ultrasonic Dissector
(Valleylab, Inc., Boulder, CO) after right portal
vein ligation. Parenchymal split was commenced
in a caudal-to-cranial fashion. The avascular groove
between the origin of right and middle hepatic
vein was dissected to define the cranial extent of
the split. A partial split was defined when paren-
chymal transection involved 50–80% of the com-
plete transection surface8 (Fig 1, A) and was the
preferred approach in the early series of our pa-
tients due to learning curve. A complete split was
defined as a full parenchymal split until the ante-
rior surface of the retrohepatic inferior vena cava
(IVC) was exposed (Fig 1, B–C). As the hepatic
transection was conducted in a caudal-to-cranial
fashion, the parenchymal split continued deep to
the right hilar plate, which was then encircled
and safeguarded. The right and left caudate were
split apart to expose the anterior surface of IVC.
An angle instrument then was passed into the avas-
cular plane along the anterior wall of retrohepatic
vena cava in order to expedite transection of the
retro-hilar plate liver tissues and safeguard the
anterior wall of retrohepatic IVC, which was
exposed upon completion of split. A low central
venous pressure was maintained during paren-
chymal transection. A leakage test was performed
via injection of methylene blue solution into the
cystic duct. Patency of right hepatic artery was
checked by Doppler ultrasound before wound
closure. The right hepatic artery and biliary
pedicle were encircled subsequently by a loop of
nonabsorbable suture to facilitate future identifica-
tion in stage II operation. No placement of plastic
bag, antiadhesive or drain was necessitated. Post-
operative care entailed a tight control of fluid bal-
ance and early resumption of oral diet as soon as
flatus was passed. Interval computed tomography
(CT) with volumetry was performed within
1 week after the stage I procedure. If insufficient
FLR hypertrophy was detected, another set of CT
volumetry would be performed 4–5 days later fol-
lowed by stage II procedure when FLR/ESLV
$35%.
Evaluation of changes in FLR volume. FLR
volumetric changes before and after the stage I
procedure were expressed in the form of absolute
gain in volume increment and changes in
FLR:ESLV ratio. FLR kinetic growth rate was
assessed by the change in volume divided by the
number of waiting days to CT volumetry
(mL/day), and gain in FLR:ESLV ratio divided by
the number of waiting days to CT volumetry (FLR/
Fig 1. (A) A 51-year-old chronic hepatitis B (HBV) carrier with a solitary 11 cm right lobe hepatocellular carcinoma and
future liver remnant/estimated standard liver volume ratio of 24.2%. Computed tomography showed a partially split
liver in stage I procedure. The hypertrophied left liver may reduce the transverse distance between the 2 transection
surfaces, rendering further transection of the remaining tissue plane in stage II more challenging. (B) A 50-year-old
HBV carrier with a solitary 5 cm right lobe hepatocellular carcinoma. Computed tomography of a completely split liver.
(C) An operative image of a completely split liver with a future liver remnant/estimated standard liver volume ratio of
19.3%.
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logic examination of the nontumorous liver tissue.
Subgroup analysis was performed to assess the
effect of ALPPS on the liver status.
Statistical analysis. All continuous variables were
expressed in median and compared with Mann-
Whitney U test. Categorical variables were
compared between groups using v2 test. Statistical
analysis was conducted by SPSS software package
version 20.0 (IBM, Armonk, NY).
RESULTS
Postoperative outcomes between complete split
and partial split. Patient demographics were de-
picted in Table I. The median age of our cohort
was 62 years old. No significant difference with re-
gard to liver function was observed between the 2
groups. Although both groups had similar tumor
size and number, the serum alpha-fetoprotein
(AFP) level was significantly higher in the com-
plete split group. The ratio of patients with com-
plete and partial split was almost 50:50
(complete, n = 13; partial, n = 12). Table II showed
the perioperative outcomes. All patients pro-
ceeded to stage II operation (complete split:
7 days versus partial split 10.5 days, P = .078)
without any inter-stage complications or mortality.
There was a trend for increased perioperative
blood loss in stage II operation for partial split
that was not present for the complete split group.
The perioperative blood loss for complete and par-
tial split in stage I was 500 mL and 537.5 mL
(P = .241), and in stage II was 350 mL and
975 mL (P = .381), respectively. The operativetimes for complete and partial split in stage I
were 385 minutes and 327 minutes (P = .289),
and in stage II were 156 minutes and 218.5 minutes
(P = .289), respectively. The overall postoperative
morbidity ($grade 3a) rate after stage II operation
was 16% (complete versus partial split: 7.7% vs
25%, P = .238) and hospital mortality rate after
stage II operation was 8% (complete versus partial
split: 0% vs 16.7%, P = .125). The causes for the 2
mortalities were multi-organ failure that occurred
on postoperative day 14 and 60.
FLR growth profiles between complete split and
partial split. Both groups shared similar size of FLR
and FLR/ESLV ratio before stage I procedure
(Table III). However, a complete split was associ-
ated with a much greater FLR growth than partial
split (Fig 2). The absolute gain in volume
(187.1 mL vs 132.6 mL, P = .022) and daily hyper-
trophy rate (31.2 vs 17.5 mL/day, P = .022) were
significantly higher in the complete split group re-
sulting in a much greater FLR:ESLV ratio (42.1%
vs 33.9%, P = .019). Moreover, the complete split
group had a much better chance to reach the
FLR:ESLV cut-off ratio (ie, 35%) for hepatectomy
within 10 days (76.9% vs 33.3%, P = .024), which
rendered them more likely to receive the stage II
operation <14 days after stage I operation
(100.0% vs 58.3%, P = .009) and resulted in a
much shorter hospital stay (17.5 vs 22 days,
P = .016).
Growth kinetics between chronic hepatitis and
cirrhosis. When stratified according to the liver
status, our findings showed that complete split
induced a more significant FLR growth than partial
Table I. Patient characteristics and tumor status
Overall
(n = 25)
Complete split (C)
(n = 13)
Partial split (P)
(n = 12)
P value
(C versus P)
Age 62 (50–80) 60 (50–80) 64 (51–80) .354
Sex (M:F) 23:2 11:2 12:0 .48
HBsAg (n) 21 (84%) 10 (83.3%) 11 (91.7%) 1.000
HCV 1 1 0
Steatohepatitis 3 2 1
Bilirubin (umol/L) 9 (5–49) 9 (5–49) 9 (5–20) .367
AST (u/L) 48 (19–254) 46 (22–254) 58 (19–98) .828
Platelet count (109/L) 166 (104–457) 207 (113–457) 150 (104–273) .072
ICG at 15 min 12.8 (7.3–30.2) 11.5 (7.3–30.2) 13.35 (7.6–16.8) .598
AFP (ng/ml) 131 (2–187,420) 860 (2–187,420) 21 (2–2,164) .022
Tumor size (cm) 7.5 (2–16) 7.5 (3–16) 7.3 (2–11) .429
Tumor no. 2 (1 multiple) 2 (1–4) 1 (1 multiple) .704
Liver status
Chronic hepatitis 12 7 5 .543
Cirrhosis 13 6 7
ICG, Indocyanine green; HBsAg, hepatitis B surface antigen positive; HCV, hepatitis C carrier; AST, aspartate aminotransferase; ICG, indocyanine green
retention rate; AFP, alpha-fetoprotein.
Table II. Intraoperative and postoperative outcomes between complete and partial split
Overall
(n = 25)
Complete split (C)
(n = 13)
Partial split (P)
(n = 12)
P value
(C versus P)
Operating time (min)
Stage I 360.0 385.0 327.0 .289
Stage II 187.0 156.0 218.5 .384
Blood loss (mL)
First stage 515.0 500.0 537.5 .241
Second stage 700.0 350.0 975.0 .381
Blood transfusion (units)
First stage 0 (0–0.96) 0 (0–0.6) 0 (0–0.96) .441
Second stage 0 (0–4.8) 0 (0–1.28) 0 (0–4.8) .31
Postoperative complications
($grade 3a)
4 (16%) 1 (adhesive
intestinal
obstruction)
3 (rebleeding from
transection surface,
n = 1; chronic liver
insufficiency, n = 1;
multiorgan failure,
n = 1)
.238
Hospital mortality 2 (8%) 0 2 .125
Hospital stay (d) 18 (12–40) 17.5 (12–25) 22 (12–40) 0.016
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phy rate and gain in FLR:ESLV ratio (Table II). Our
findings also showed that ALPPS could induce FLR
hypertrophy in cirrhotic livers within a short period
of time. However, despite the fact that complete split
tended to induce a more rapid FLR hypertrophy
than partial split in cirrhosis (hypertrophy rate
32.2 mL/day vs 16.9 mL/day, P = .086), the differ-
ence was less obvious for cirrhotic livers (FLR/
ESLV% increment: 14.8% vs 11.0%, P = .668) than
for chronic hepatitis (FLR/ESLV% increment:
18.1% vs 11.3%, P = .042).Liver function recovery after stage I and II
procedure. Serum bilirubin returned to near
normal level before stage II operation for both
complete and partial split. However, a complete
split tended to induce a higher serum bilirubin
level from the first to fourth postoperative day after
stage I procedure, but a significantly faster return
towards normal serum levels from the second to
fifth day after stage II procedure (Fig 3, A). A
reciprocal phenomenon was observed in the par-
tial split group when the liver function recovered
faster after stage I operation but a significantly
Table III. FLR growth kinetics between complete and partial split
Overall (n = 25) Complete split (C) (n = 13) Partial split (P) (n = 12)
P value
(C versus P)
FLR
Before stage I 297.0 (181.9–524.0) 292.0 (181.9–524.0) 307.8 (200.0–410.0) .870
After stage I 498.3 (316.0–795.7) 519.7 (360.0–795.7) 403.5 (316.0–565.2) .073
ESLV (mL) 1,239.2 (1,080.8–1,440.3) 1,239.2 (1,080.8–1,440.3) 1,221.9 (1,084.1–1,429.2) .957
FLR/ESLV%
Before stage I 24.6 (15.7–37.1) 24.9 (16.7–37.1) 23.6 (15.7–36.5) .828
After stage I 38.5 (26.7–56.9) 42.1 (32.7–56.9) 33.9 (26.7–50.5) .019
Gain in volume (mL) 155.2 (67.3–348.4) 187.1 (73.8–348.4) 132.6 (67.3–205.4) .022
Gain in FLR/ESLV%
All patients 14.5 (6.7–39.6) 18.1 (6.7–30.7) 11.1 (6.7–39.6) .064
Chronic hepatitis 18.1 (14.5–27.5) 11.3 (8.3–15.8) .042
Cirrhosis 14.8 (6.7–30.7) 11.0 (6.7–39.6) .668
Gain in FLR/ESLV%/
day
All patients 2.0 (0.5–6.1) 2.6 (0.8–6.1) 1.5 (0.52–2.8) .001
Chronic hepatitis 3.1 (2.1–4.6) 1.7 (0.7–1.9) .004
Cirrhosis 2.3 (0.8–6.1) 1.3 (0.5–2.8) .090
Hypertrophy rate (%
volume gain/day)
All patients 6.0 (1.6–23.4) 11.5 (3.2–23.4) 5.5 (1.6–11.7) .011
Chronic hepatitis 11.5 (5.9–19.7) 5.7 (3.8–6.0) .007
Cirrhosis 8.3 (3.2–23.4) 5.4 (1.6–11.7) .283
No. of patients
reaching $35%
ESLV in 10 d
10 (76.9%) 4 (33.3%) .024
No. of patients
receiving stage
II <14 d
13 (100%) 7 (58.3%) .009
ESLV, Estimated standard liver volume; FLR, future liver remnant.
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postoperative day, and a higher serum Aspartate
aminotransferase (AST) level from the first to
third and sixth postoperative day after stage II
operation (Fig 3, B).
Left portal flow hemodynamic changes during
stage I procedure. Portal flow was measured by
intraoperative Doppler ultrasonography routinely
for the last 9 patients of our cohorts in order to
study the relationship of flow dynamics and FLR
hypertrophy (Fig 4). The portal pressure increased
substantially from 7.0 mm Hg (4–22 mm Hg) to
16 mm Hg (4–23 mm Hg) after right portal vein
ligation (P = .028). The median left portal flow
per 100 gm of FLR increased substantially from
76.6 mL/100 gm/min (52–182.9 mL/100
gm/min) to 193.7 mL/100 gm/min (132.2–325.2
mL/100 gm/min) after right portal vein ligation
and further increased to 259 mL/100 gm/min
(106.6–459.8 mL/100 gm/min) after in situ split
(P = .008). The left portal flow then significantly
decreased to 80.4 mL/100 gm/min (66.4–192.9mL/100 gm/min) over a median of 10 days (6–70
days) in stage II operation (P = .021) by autoregu-
lation. Nonetheless, subgroup analysis according
to the split completeness was not feasible due to
the small sample size.DISCUSSION
The recent introduction of ALPPS procedure
has revolutionized the management of patients
with small-for-size FLR contemplating for major
hepatectomy.1,2 However, the initial experience
mainly was ascribed to colorectal liver metastasis
or other malignant tumors in non-cirrhotic
livers,6,7 and data on its application to HCC arising
from background chronic liver diseases is relatively
scarce.11 Recently, we have reported our experi-
ence of ALPPS for hepatitis B-related HCC result-
ing in a 47% volume increment in 7 days.12
Nonetheless, it seemed that the degree of
hypertrophy in chronic liver diseases was not as
substantial as in non-cirrhotic livers ranging from
Fig 2. Growth kinetics between a complete and partial split.
Fig 3. (A) The trend of serum bilirubin during an associating liver partition and portal vein ligation for staged hepa-
tectomy procedure. (B) The trend of serum aspartate aminotransferase during an associating liver partition and portal
vein ligation for staged hepatectomy procedure.
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of the lesser extent of FLR tissue growth in chronic
hepatitis compared with that in non-cirrhotic
livers, it was imperative to investigate for factors
that might affect FLR hypertrophy. From the sur-
geons’ perspectives, it would be pertinent to
know if the degree of in situ split would have an
impact on FLR hypertrophy, because it would
determine the operative strategy for parenchymal
transection and the timing of stage II procedure.
The findings of our study showed that a complete
split induced a more significant FLR hypertrophy
than partial split, with a tendency to perform thestage II operation much earlier and a quicker re-
covery of liver function after stage II operation.
Despite the significant FLR growth, a complete
split was shown to be as safe as a partial split
without increased morbidity and mortality.
A complete split had several merits. The objec-
tive for “complete” portal flow diversion from a
technical perspective was achieved, and therefore,
no uncertainty on the effectiveness of the stage I
procedure remained, even when adequate FLR
hypertrophy failed to occur. Second, it rendered
the stage II operation a much “cleaner” operation
without the need for revisiting a semi-transected
Fig 4. Changes in portal flow dynamics during an associ-
ating liver partition and portal vein ligation for staged
hepatectomy procedure. RPV, Right portal vein.
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function after stage II operation as shown by an
earlier return of serum bilirubin and aspartate
aminotransferase to normal levels. More impor-
tantly, a higher FLR volume was attained within a
short period of time, and hence improving the
safety margin for major hepatectomy against post-
operative liver failure while the possible technical
challenges from an exceedingly delayed stage II
operation was avoided.
It remained unclear if the issue of learning
curve would affect the outcome of ALPPS. Partial
split, as adopted more frequently in the early phase
of our ALPPS program was shown to have a
tendency of heavier blood loss in stage II operation
and mortalities than complete split. However,
given the operative technique for parenchymal
transection with ultrasonic dissector in ALPPS was
no different from conventional hepatectomy, we
thought that it was the bleeding from transection
of a recently traumatized incomplete transection
surface left from stage I operation rather than
immature transection techniques to account for
the difference in blood loss between the 2 groups.
Besides, the 2 mortalities in partial ALPPS
occurred in different eras of the study period
and the so the issue of the learning curve affecting
the short-term outcome seemed to be unlikely.
The learning curve, in our opinion, seemed pre-
dominantly to affect the operative strategy to reach
a complete split and the decision for the timing of
the second operation.
Timing of the second operation, in our opinion,
was regarded as an important factor that deter-
mined its technical difficulty. It was conceivable
that the longer interval for stage II operation, the
more technically challenging in terms of adhesiol-
ysis and parenchymal transection will become.
One partial split patient in the present cohort
even had the 2 partially transection surfaces fusedtogether when stage II operation was performed at
70 days after stage I operation due to slow FLR
hypertrophy. On the other hand, a significantly
higher proportion of patients in the complete split
group were able to attain adequate FLR hypertro-
phy and became eligible for stage II operation
within 14 days after stage I operation. Hence, a
complete split should be considered whenever
possible if substantial FLR growth was necessary
to ensure postoperative recovery of liver function.
When comparing our findings with the 202
patients reported from the International ALPPS
Registry,6 it was worthwhile to highlight that the
FLR growth kinetics of the present cohort corrobo-
rated well with those from the registry. Although
standardization of operative technique may be diffi-
cult in such large cohorts from different centers in
the registry, the consistency of findings between our
study and Schadde et al6 suggested it was unlikely
that our results regarding split completeness could
not be generalized to all patients.
Nonetheless, the rapid FLR hypertrophy
induced by the ALPPS procedure was not under-
stood entirely. Redistribution of portal blood flow
as well as release of growth factors in response to
tissue injury were thought to be the 2 main
mechanisms that accounted for the rapid liver
regeneration.8 Based on the notion that portal
vein embolization induced FLR hypertrophy via
flow augmentation.13 Flow dynamics was investi-
gated and the same phenomenon in substantial
FLR portal flow increment after ALPPS was
observed in our study. Whether the degree of por-
tal flow changes correlated with the split complete-
ness remained unclear. However, the difference in
the speed of FLR hypertrophy between complete
and partial split was less obvious in cirrhosis
when compared with chronic hepatitis. From the
experience on small-for-size liver grafts in living
donor liver transplantation,14 it was postulated
that while FLR portal flow augmentation would
be favorable for hypertrophy in chronic hepatitis,
this phenomenon might be detrimental to
cirrhotic liver tissues as the shear force exerted
by the enhanced portal flow on diseased hepatic
sinusoids could be less favorable for tissue regener-
ation in background cirrhosis. As such, an intrao-
perative left liver biopsy should be necessitated
during stage I procedure in order to guide the sur-
geons to predict the degree of FLR hypertrophy
and the timing of the second operation. A longer
interval to stage II operation may be desirable for
cirrhotic livers to allow sufficient liver hypertrophy
and cellular restructuring.12,15 Nonetheless, the
change in portal hemodynamics during ALPPS
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tional studies for evaluation.
There are several limitations to our study. The
findings from such a small sample size required
further validation in larger cohort. The nonsignif-
icant difference in morbidity and mortality be-
tween the 2 approaches could be related to a type
II error. Selection bias also should be considered,
as partial split was favored in the early phase of the
ALPPS program. Despite the potential benefits,
there are situations when a complete split may not
be possible due to difficulty in parenchymal
transection. For instance, a sizeable tumor in right
anterior section stretching the middle hepatic vein
could induce significant venous bleeding during in
situ split for an extended right hepatectomy. A
tumor located close to the IVC or caudate also
would render a complete split down to the IVC not
feasible. In these situations, a partial split may be
preferred, and the likelihood of a slow FLR
hypertrophy leading to a delayed stage II opera-
tion would be expected.
In conclusion, complete-ALPPS induced more
rapid FLR hypertrophy than partial-ALPPS without
increased perioperative risk in CLD. As FLR hyper-
trophy was less substantial for CLD than for normal
livers, complete-ALPPS should be preferred for
hepatitis-related HCC in order to achieve an
optimal outcome.REFERENCES
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